Sandra Horning, MD
Alectinib (Alecensa) reduced the risk of disease progression or death compared with crizotinib (Xalkori) as a frontline treatment for patients with ALK
-positive non–small cell lung cancer (NSCLC), according to findings from the phase III ALEX trial.
-positive NSCLC who had progressed following treatment with platinum-based chemotherapy and crizotinib.
Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. Presented at: 2016 ASCO Annual Meeting; June 3-7, 2016; Chicago. Abstract 9008.
... to read the full story